Filter by
Filter by
Executive Summary of Clinical and Technical Guidelines for Esophageal Cancer Proton Beam Therapy From the Particle Therapy Co-Operative Group Thoracic and Gastrointestinal Subcommittees.
In this guideline document, the dosimetric data and clinical evidence of PBT for esophageal cancer (EC) was summarized and evaluated. The clinical outcome data...
Treating gastrointestinal malignancy with proton therapy
The improved dosimetry with proton therapy enables greater sparing of normal tissues...
FLASH Radiotherapy: What Can FLASH's Ultra High Dose Rate Offer to the Treatment of Patients With Sarcoma?
A review article by the Upenn group summarized the preclinical and clinical evidence for the FLASH effect and discussed the potential clinical significance for...
Vision loss following high-dose proton-based radiotherapy for skull-base chordoma and chondrosarcoma
This study included148 chordoma and chondrosarcoma patients and 283 individual eyes with functional vision at baseline who received a minimum 30GyRBE to 0.1cm3...
Definitive high-dose, proton-based radiation for unresected mobile spine and sacral chordomas.
Sixty-seven patients with unresected spinal chordomas treated with PBT were evaluated. With a median follow-up of 56.2 months, 5- and 8-year OS were 83.5 % and...
A phase II trial of hypofractionated high-dose proton beam therapy for unresectable liver metastases.
This study analyzed 46 patients with 49 liver metastases treated by PBT to a total dose of 60 GyRBE in 5 fractions (BED 132 GyE) or 70 GyRBE in 10 (BED 119 GyE)...